<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273672</url>
  </required_header>
  <id_info>
    <org_study_id>H00011523</org_study_id>
    <nct_id>NCT04273672</nct_id>
  </id_info>
  <brief_title>Speech, Linguistic and Acoustic Markers in Parkinson's Disease</brief_title>
  <acronym>SLAM-PD</acronym>
  <official_title>Speech, Linguistic and Acoustic Markers in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sonde Health, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts Institute of Technology/Lincoln Labs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to identify speech and language markers that provide information on cognitive function
      and predict cognitive decline in Parkinson's disease. We will administer various speech tasks
      and cognitive assessments to participants with Parkinson's disease and healthy controls. We
      will also explore the associations between genetic factors and speech and cognitive status in
      Parkinson's disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>We will develop a regression model using speech acoustic parameters to classify PD participants by cognitive status (mild cognitive impairment [MCI] vs. normal cognition)</measure>
    <time_frame>12-24 months</time_frame>
    <description>We will use a Gaussian regression model and other machine learning techniques to develop a model including fundamental frequency, noise-to-harmonic ratio, cepstral peak prominence, formants, phoneme-dependent speaking rates and diadochokinesis rate and quality to predict categorization of PD participants by disease and cognitive status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>We will measure the difference in number and duration of within-utterance pauses, and pauses before verbs in PD participants with and without mild cognitive impairment</measure>
    <time_frame>12-24 months</time_frame>
    <description>Participants will produce speech samples of spontaneous speech, which will be transcribed and coded for pause length and location, and these characteristics will be entered into a non-linear mixed model with the three-level predictor of group membership (control, PD-MCI, PD with normal cognition) as the parameter of interest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>We will measure syntax processing efficiency score (percentage correctly understood sentences/processing time) in controls, and in PD with and without MCI</measure>
    <time_frame>12-24 months</time_frame>
    <description>When presented with sentences of varying syntactical complexity in a self-paced task, participants response time and accuracy will be used to create multilevel models and test for effect of group (controls, PD, PD-MCI).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Cognitive Impairment, Mild</condition>
  <condition>Speech</condition>
  <arm_group>
    <arm_group_label>Parkinson's Disease</arm_group_label>
    <description>Subjects with Parkinson's Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Subjects without Parkinson's Disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cognitive Battery</intervention_name>
    <description>Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Parkinson's Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Voice, Speech and Language Analysis</intervention_name>
    <description>Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Parkinson's Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires and Clinical Assessments</intervention_name>
    <description>Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Parkinson's Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA Analysis</intervention_name>
    <description>Participants will have their blood drawn for DNA analysis.</description>
    <arm_group_label>Parkinson's Disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with Parkinson's Disease and mild cognitive impairment or normal cognition as well
        as controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parkinson's Disease (or healthy control)

          -  Disease duration â‰¥ 2 years

          -  Mild cognitive impairment or normal cognition

        Exclusion Criteria:

          -  Diagnosis of dementia (MoCA &lt;21)

          -  Adults unable to consent

          -  Age &lt; 18

          -  Pregnant women

          -  Prisoners

          -  Non-English speakers

          -  Any neurological disorder other than PD

          -  Deep brain stimulator placement

          -  Severe, unstable psychiatric disorder

          -  Unintelligible speech due to effects of PD

          -  Visual acuity or color vision impairment that would interfere with cognitive testing

          -  Other voice, speech or swallowing disorders or history of surgery involving
             palate/nasopharynx/larynx/vocal cords
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kara Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kara Smith, MD</last_name>
    <phone>508-856-2527</phone>
    <email>kara.smith@umassmemorial.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meaghan Demers-Peel, BS</last_name>
    <phone>774-445-6568</phone>
    <email>meaghan.demers-peel@umassmed.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMass Medical School/UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Kara Smith</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

